NL
DE
31 January 2018
For patients to take care of their own health, they need insight into the two most important factors that determine a successful treatment of their chronic myeloid leukemia: firstly, adherence to therapy, and secondly, an adequate monitoring of their disease. Patients can monitor their own therapy adherence using the CMyLife Medapp.
They can then share the results electronically with their treating physician, including a logbook of the side effects they have experienced from the oral chemotherapy. To ensure adequate disease monitoring with patients in the lead, a guideline app is developed that warns patients when they need to get their blood checked. Using the hospital’s laboratory values the app then informs patients whether the effect of their treatment is optimal or not, and what actions to take. This app is completely aligned with the national Dutch guideline for chronic myeloid leukemia.
Besides the further development of these apps, this project explores facilitating and hindering factors for the implementation and scaling up of CMyLife in general. This will result in an action plan for accelerated nationwide implementation, written under the guidance of implementation expert Rosella Hermens of IQhealthcare. Geneviève Ector is a medical doctor training as an haematologist, and she conducts another pillar of the ZonMw project as part of her PhD. “Earlier research suggests that medical doctors consider the effectiveness of CMyLife a crucial factor for its implementation in to their own practice”, according to Ector. “We therefore decided to measure the effectiveness of CMyLife: does it actually improve patient empowerment, treatment and guideline adherence and quality of life?”. Finally, this project fully engages the knowledge transfer of its findings, so other organizations and innovators can benefit fully.
CMyLife was recently awarded a ZonMw grant of 200,000 euro within the program Quality in Health Care. The grant will be used to further develop CMyLife’s innovations, and to scale up its nationwide implementation using action research.
For patients to take care of their own health, they need insight into the two most important factors that determine a successful treatment of their chronic myeloid leukemia: firstly, adherence to therapy, and secondly, an adequate monitoring of their disease. Patients can monitor their own therapy adherence using the CMyLife Medapp.
They can then share the results electronically with their treating physician, including a logbook of the side effects they have experienced from the oral chemotherapy. To ensure adequate disease monitoring with patients in the lead, a guideline app is developed that warns patients when they need to get their blood checked. Using the hospital’s laboratory values the app then informs patients whether the effect of their treatment is optimal or not, and what actions to take. This app is completely aligned with the national Dutch guideline for chronic myeloid leukemia.
Besides the further development of these apps, this project explores facilitating and hindering factors for the implementation and scaling up of CMyLife in general. This will result in an action plan for accelerated nationwide implementation, written under the guidance of implementation expert Rosella Hermens of IQhealthcare. Geneviève Ector is a medical doctor training as an haematologist, and she conducts another pillar of the ZonMw project as part of her PhD. “Earlier research suggests that medical doctors consider the effectiveness of CMyLife a crucial factor for its implementation in to their own practice”, according to Ector. “We therefore decided to measure the effectiveness of CMyLife: does it actually improve patient empowerment, treatment and guideline adherence and quality of life?”. Finally, this project fully engages the knowledge transfer of its findings, so other organizations and innovators can benefit fully.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
KWF grant for better selection of individuals and lung nodules in lung cancer screening
1 November 2021 The Dutch Cancer Society has awarded the consortium project ‘Multi-source data approach for Personalized Outcome Prediction in lung cancer screening’ with a grant of 1,425,000 Euro. Colin Jacobs will lead the work package on using artificial intelligence for accurate risk estimation of lung nodules. read more
Radiation boost lowers risk of prostate cancer recurrence
21 January 2021 An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost. read more
650,000 Euro funding for research into the phasing out of medication for leukaemia patients
30 July 2020 With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice. read more
Improved method for detecting lung cancer
24 July 2020 Radboudumc researchers are the only ones in the Netherlands using a new method to make better lung cancer diagnoses earlier stage. Erik van der Heijden and Roel Verhoeven shows that the use of flexible imaging equipment via the natural respiratory tract contributes to a more accurate diagnosis. read more
Optimizing workup in head and neck cancer (HNC)
23 July 2020 In the journal Cancer RIHS researcher Henrieke Schutte described the outcomes after the implementation of a fast-track multidisciplinary integrated HNC care program: time-to-treatment was significantly reduced and survival and patient satisfaction increased significantly without increasing costs. read more
